Meeting
2021 Gastrointestinal Cancers Symposium
Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.
Authors
Mehmet Akce
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
Mehmet Akce , Manali Rupji , Jeffrey M. Switchenko , Walid Labib Shaib , Christina Wu , Olatunji B. Alese , Maria Diab , Gregory B. Lesinski , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03800602
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 95)
DOI
10.1200/JCO.2021.39.3_suppl.95
Abstract #
95
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment.
First Author: Vanessa Costa Miranda
Poster
2022 ASCO Annual Meeting
Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Nicolas Huyghe
Poster
2020 ASCO Virtual Scientific Program
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
First Author: Georg Martin Haag
Poster
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
First Author: Yasutoshi Kuboki